The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 150.00
Bid: 140.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 20.00 (14.286%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 150.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Future Surges As It Sees Results In Line

Fri, 20th Mar 2020 10:49

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - WINNERS

----------

InterContinental Hotels Group, up 11%. The Holiday Inn and Crowne Plaza owner said demand is currently at the lowest level it has ever seen. To combat this, IHG is hoping to save about USD150 million through salary cuts, including "substantial" reduction in salary and incentives from its board and executive committee. Also, IHG will pull its final dividend of 85.9 US cents - saving about USD150 million - and said it will delay any further dividends until "visibility has improved". The hotel owner will also delay renovations and relax brand standards. Turning to trading, IHG said its global revenue per available room was down 6% in January and February, with a flat performance in the US being offset by a catastrophic drop in Greater China. In February, RevPAR in Greater China was down 90% year on year.

----------

Carnival, up 5.2%. The cruise operator said revenue for the first quarter increased 2.1% to USD4.8 billion from USD4.7 billion a year ago. However, Carnival swung to a first-quarter loss, with earnings dented by disruption due to the early days of the current Covid-19 pandemic. The company recorded a GAAP net loss of USD781 million, or USD1.14 per share, for the quarter ended February 29. This compares to net income of USD336 million, or earnings per share of USD0.48, for the first quarter a year ago. The impact of Covid-19 on the first quarter's net loss was around USD0.23 per share, the firm said, taking into account cancelled voyages and disruptions. Carnival said Covid-19 will have a "material negative impact" on its financial results and liquidity.

----------

FTSE 250 - WINNERS

----------

Future, up 30%. The media company said declines in its travel magazine portfolio have been offset by its grocery titles, resulting in "strong" digital audience numbers. "The period started well with exceptionally strong digital audience numbers with the resultant beneficial flow through to eCommerce and digital advertising," Future said. As a result, the company expects its results for the six months to the end of March to be in line with internal expectations. "The recent weeks have been unprecedented. However, our business has continued to trade robustly, with the diversified strategy working well. As of today, we have seen limited impact on our digital revenues," Future said. Despite the "robust" trading, Future said it is implementing some profit protection measures.

----------

JD Wetherspoon, up 27%. The pub chain operator reported a rise in profit and revenue in the first half of its financial year, but has cancelled its dividend due to the uncertainty surrounding the Covid-19 outbreak. In the 26 weeks to January 26, Wetherspoon's recorded pretax profit of GBP57.9 million, up 15% from the GBP50.3 million seen in the same period the year before. Revenue was 4.9% higher year-on-year at GBP933.0 million from GBP889.6 million. Like-for-like sales in the first half of the financial year were 5.0% higher. Like-for-like bar sales increased by 4.2%, food sales by 5.6% and fruit/slot machines by 20%. Like-for-like hotel room sales decreased by 1.3%, however. Bar sales were 60% of total sales, Wetherspoons noted. Despite the strong performance, the bar owner has cancelled its interim dividend - owing to the uncertainty caused by the spread of Covid-19.

----------

FTSE 250 - LOSERS

----------

Inchcape, down 3.1%. The automotive retailer said it will suspend its share buyback programme due to uncertainty arising from the Covid-19 outbreak. Inchcape has completed around GBP25 million of the GBP150 million repurchase programme but will serve notice to its brokers to terminate the buyback effective from next Tuesday. "Inchcape has a strong balance sheet and remains committed to its disciplined capital allocation policy, but the board believes this is the right decision at this time," the company said. As at the end of 2019, the company had cash of GBP423.0 million with total assets valued at GBP4.46 billion.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Faron Pharma, up 16%. The Finnish drug discovery company said its assets increased to EUR1.6 million in 2019 compared to just EUR400,000 reported a year earlier. As at December 31, the company said it had cash balances of EUR7.1 million compared to EUR4.1 million the year before. As a result, pretax loss narrowed to EUR13.3 million from EUR20.1 million year-on-year. The company did not generate any revenue during the year as it is currently focused on the development of Clevegen, a novel cancer immunotherapy.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Christie Group, down 5.5%. The financial services provider said it expects its 2019 results to be in line with expectations. The company said it has benefited from the profitable sale of an office building, as mentioned in our Interim results statement. However, Christie noted that its business - which operate in the hospitality, retail, medical and educational fields - took a hit from the Covid-19. This is primarily as a result of having limited access to certain of its clients' premises. "It is not currently possible to quantify the full effect of Covid-19 related disruption on our business for 2020 or beyond," said Christie in its statement Friday.

----------

Tracsis, down 1.7%. The traffic data provider said it is not possible to accurately quantify the impact on the second-half trading and therefore full year expectations amid rapidly changing situation with coronavirus. Tracsis said it expects the Rail Technology & Services division to have resilience as it derives most of its income from highly recurring product sales. However, parts of the Traffic & Data Services division are forecast to be hurt by Covid-19. In particular, the company's events businesses SEP and CTM both derive a significant amount of revenue from major UK based outdoor events, and in recent days Tracsis said it has been notified by some major clients that events scheduled for this summer will either be cancelled or postponed to the autumn. Tracsis said it expects further events to be cancelled or postponed in due course.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
13 Mar 2024 11:52

Faron Pharmaceuticals reports year of clinical progress

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals reported a year of strong progress on Wednesday, with significant overall response rates seen in both previously hypomethylating agent (HMA)-failed and higher-risk myelodysplastic syndrome (MDS) patient populations in the phase one part of the BEXMAB study.

Read more
6 Mar 2024 16:06

UK earnings, trading statements calendar - next 7 days

Thursday 7 March 
Admiral Group PLCFull Year Results
Aviva PLCFull Year Results
Beazley PLCFull Year Results
Brooks Macdonald Group PLCHalf Year Results
Coats Group PLCFull Year Results
Darktrace PLCHalf Year Results
Elementis PLCFull Year Results
Entain PLCFull Year Results
Funding Circle Holdings PLCFull Year Results
Harbour Energy PLCFull Year Results
ITV PLCFull Year Results
Kier Group PLCFull Year Results
Melrose Industries PLCFull Year Results
Nexus Infrastructure PLCFull Year Results
PageGroup PLCFull Year Results
Physiomics PLCHalf Year Results
Rentokil Initial PLCFull Year Results
Robert Walters PLCFull Year Results
Spirax-Sarco Engineering PLCFull Year Results
TT Electronics PLCFull Year Results
Tyman PLCFull Year Results
Friday 8 March 
Informa PLCFull Year Results
Just Group PLCFull Year Results
LMS Capital PLCFull Year Results
Stelrad Group PLCFull Year Results
Monday 11 March 
HgCapital Trust PLCFull Year Results
Mincon Group PLCFull Year Results
MTI Wireless Edge LtdFull Year Results
Tuesday 12 March 
BATM Advanced Communications LtdFull Year Results
Costain Group PLCFull Year Results
Domino's Pizza Group PLCFull Year Results
Fonix Mobile PLCHalf Year Results
Foresight Solar Fund LtdFull Year Results
Genuit PLCFull Year Results
H&T Group PLCFull Year Results
Hill & Smith PLCFull Year Results
MaxCyte IncFull Year Results
Persimmon PLCFull Year Results
Synthomer PLCFull Year Results
Target Healthcare REIT PLCHalf Year Results
TI Fluid Systems PLCFull Year Results
TP ICAP Group PLCFull Year Results
Wednesday 13 March 
4imprint Group PLCFull Year Results
Advanced Medical Solutions Group PLCFull Year Results
Balfour Beatty PLCFull Year Results
Centaur Media PLCFull Year Results
Faron Pharmaceuticals LtdFull Year Results
Ferrexpo PLCFull Year Results
Gym Group PLCFull Year Results
Hochschild Mining PLCFull Year Results
IP Group PLCFull Year Results
Keywords Studios PLCFull Year Results
Kin & Carta PLCHalf Year Results
Metro Bank Holdings PLCFull Year Results
Nexteq PLCFull Year Results
PensionBee Group PLCFull Year Results
Public Policy Holding Co IncFull Year Results
Seraphim Space Investment Trust PLCHalf Year Results
Supermarket Income REIT PLCHalf Year Results
Trainline PLCTrading Statement
Vaalco Energy IncFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.

Read more
4 Mar 2024 19:59

TRADING UPDATES: Beowulf raises funds for Kallak iron ore project

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
4 Mar 2024 10:40

Faron Pharmaceuticals shores up cash with EUR 3.2m convertible loans

(Sharecast News) - Faron Pharmaceuticals announced on Monday that it has successfully secured binding commitments for convertible loans totalling €3.2m from a select group of existing shareholders.

Read more
27 Feb 2024 21:12

TRADING UPDATES: Armadale Capital eyes Mahenge project financing

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
22 Feb 2024 14:26

UK earnings, trading statements calendar - next 7 days

Friday 23 February 
City of London Investment Group PLCHalf Year Results
Irish Residential Properties REIT PLCFull Year Results
Standard Chartered PLCFull Year Results
Monday 26 February 
Base Resources LtdHalf Year Results
Bunzl PLCFull Year Results
EnSilica PLCHalf Year Results
Kosmos Energy LtdFull Year Results
Made Tech Group PLCHalf Year Results
Tristel PLCHalf Year Results
Tuesday 27 February 
abrdn Equity Income Trust PLCFull Year Results
abrdn PLCFull Year Results
Croda International PLCFull Year Results
Kitwave Group PLCFull Year Results
McBride PLCHalf Year Results
PCI-PAL PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Synectics PLCFull Year Results
Uniphar PLCFull Year Results
Unite Group PLCFull Year Results
Wednesday 28 February 
AB Dynamics PLCTrading Statement
ASA International Group PLCTrading Statement
Aston Martin Lagonda Global Holdings PLCFull Year Results
Avingtrans PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Derwent London PLCFull Year Results
Glenveagh Properties PLCFull Year Results
Grit Real Estate Income Group LtdHalf Year Results
Harmony Energy Income Trust PLCFull Year Results
Hutchmed China LtdFull Year Results
International Personal Finance PLCFull Year Results
Just Eat Takeaway.com NVFull Year Results
Primary Health Properties PLCFull Year Results
Reckitt Benckiser Group PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
RHI Magnesita NVFull Year Results
St James's Place PLCFull Year Results
Taylor Wimpey PLCFull Year Results
Thursday 29 February 
Cairn Homes PLCFull Year Results
CVS Group PLCFull Year Results
Drax Group PLCFull Year Results
Faron Pharmaceuticals LtdFull Year Results
Haleon PLCFull Year Results
Hammerson PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Hunting PLCFull Year Results
International Biotechnology Trust PLCFull Year Results
London Stock Exchange Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Man Group PLCFull Year Results
Mobico Group PLCFull Year Results
Nexus Infrastructure PLCFull Year Results
Ocado Group PLCFull Year Results
PPHE Hotel Group LtdFull Year Results
Schroder Oriental Income Fund LtdFull Year Results
Schroders PLCFull Year Results
Serco Group PLCFull Year Results
Shaftesbury Capital PLCFull Year Results
Spectris PLCFull Year Results
Spire Healthcare Group PLCFull Year Results
Vesuvius PLCFull Year Results
Weir Group PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
19 Feb 2024 11:23

Faron discloses events of default on debt obligations to lender

(Alliance News) - Faron Pharmaceuticals Ltd shares fell on Monday, after it said it is in breach of several undertakings agreed in a secured debt deal with lender IPF Fund II SCA, SICAV-FIAR.

Read more
25 Jan 2024 20:09

TRADING UPDATES: Microsaic completes acquisition; Narf revenue soars

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
9 Jan 2024 12:36

Faron launches second phase of leukaemia treatment trial

(Sharecast News) - Faron Pharmaceuticals has initiated phase two of the BEXMAB trial, it announced on Tuesday, marking a significant milestone in its cancer treatment development programme.

Read more
9 Jan 2024 10:56

Faron says first patient dosed in phase two Bexmab trial for cancer

(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday announced that the first patient has been dosed in phase 2 of its Bexmab trial.

Read more
11 Dec 2023 13:22

Faron unveils promising antibody study results

(Sharecast News) - Faron Pharmaceuticals unveiled promising phase one data from its BEXMAB study in myeloid malignancies during the 65th American Society of Hematology (ASH) annual meeting, it announced on Monday.

Read more
11 Dec 2023 12:01

Faron Pharmaceuticals hails positive results of cancer drug trial

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said results from a probe of a cancer drug were promising.

Read more
7 Dec 2023 19:33

IN BRIEF: Faron Pharma celebrates publication of bexmarilimab results

Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Says that results from its Phase 1/2 MATINS trial of bexmarilimab have been published in Cell Reports Medicine, an open-access journal. According to the trial, bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumours. It also showed that CLEVER-1 targeting is safe and well-tolerated with no serious adverse effects, and that bexmarilimab induced macrophage activation and increased IFNy signalling in patients who achieved disease control and prolonged survival.

Read more
7 Dec 2023 11:01

Faron publishes cancer immunotherapy study findings

(Sharecast News) - Faron Pharmaceuticals announced the publication of the comprehensive findings from the groundbreaking phase one and two 'MATINS' trial of bexmarilimab on Thursday - its humanised monoclonal anti-CLEVER-1 antibody aimed at transforming the landscape of anticancer immunotherapies.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.